For those pharmacy practitioners with a keen interest in the evolving market of biologic and biosimilar therapeutics, 2015 promises to introduce some interesting developments. As has been recently reported, advisors to the US Food and Drug Administration are meeting in March to review a medication from the South Korean-based company, Celltrion, for their biosimilar—Remsima—a biologic version of Johnson & Johnson and Merck & Co’s anti-inflammatory blockbuster, Remicade (infliximab). The filing from this past August was the first for a monoclonal antibody using the FDA’s new biosimilar pathway.
PP&P has covered biosimilar topics for some time now and will continue to keep you abreast of developments in this intriguing field. As we follow the FDA’s actions, please visit our Web site—www.pppmag.com—and search for biosimilars. Although adoption of biosimilars likely will happen slowly, pharmacy should be planning now for the impact of biosimilar approvals. Taking the time now to prepare for this transition will ease the process as approvals occur.
As always, PP&P encourages best practices when it comes to medication selection and handling. If you have any specific questions or concerns related to biosimilar adoption in the hospital setting, please feel free to let us know.
All the best,
R. Mitchell Halvorsen
P.S. We would like to congratulate Jim Walsh, BS Pharm, the pharmacy director at Mercy San Juan Medical Center in Carmichael, California. After participating in PP&P’s Going Green survey, Jim was the randomly selected winner of a Garmin Fitbit Flex. Congratulations Jim and a heartfelt thanks to all the pharmacy directors who participate in PP&P surveys. The data we collect help establish practice benchmarks, and the chance to win a great prize isn’t bad either!